key: cord-0698211-p5g6cap1
authors: Flower, Dr Luke; Olusanya, Dr Olusegun; Madhivathanan, Dr Pradeep R
title: The Use of Point of Care Lung Ultrasound and Echocardiography in the Management of COVID-19
date: 2020-05-15
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2020.05.009
sha: e2b3f534f21e7ba1dfb994e94e47536b1b8d55e4
doc_id: 698211
cord_uid: p5g6cap1

nan

The Use of Point of Care Lung Ultrasound and Echocardiography in the Management of COVID-19

Over the past few months, COVID-19 has provided an unprecedented challenge to critical care teams across the world. As the number of cases increase exponentially, we are seeing an unparalleled strain on intensive care resources.

In order to ensure optimal patient care we require rapid, reliable and low risk diagnostic imaging.

Whilst computed tomography (CT) can aid with diagnosis, the volume of critically unwell and highly infective patients means mass CT scanning is unlikely to be a safe or practical approach. The critical care community has thus acknowledged the importance of point of care ultrasonography (POCUS) in the management of COVID-19, specifically lung ultrasound (US) and transthoracic echocardiography (TTE).

Current reports of lung US findings secondary to SARS-CoV2 infection appear to demonstrate correlation to disease stage and phenotype (figure 1). Italian intensivist Gio Volpicelli also described its sensitivity in identifying COVID-19, even in patients whom RT-PCR swabs returned negative (personal communication, April 2020). The precise protocol for lung POCUS is still debated, with the current UK Intensive Care Society (ICS) guidelines suggesting a six-view approach (apical, basoanterior and posterior-lateral views bilaterally) and providing advice regarding probe decontamination (1, 2) .

In early disease, initial findings include the presence of focal B-lines interspersed with areas of healthy lung and A-lines (1). An irregular and thickened pleura with sub-pleural consolidation may also be seen (3) . If there is no oxygen requirement, these patients may be suitable for discharge. (2) In moderate disease an increased number of confluent B-lines may be visible, with loss of A-lines.

Such patients are likely to require supplementary oxygen and admission. These patients may fit the "L" phenotype and require moderate PEEP ventilation strategies, with conservative fluid balance (2-4).

As the disease progresses, lobar and trans-lobar consolidation may be seen, with the possibility of associated pleural effusions (large effusions are rare and a poor prognostic indicator). These patients are likely to require critical care admission and appear to fit the "H" phenotype, with high PEEP, early proning and conservative fluid strategies possibly beneficial (2) (3) (4) . The dynamic nature of this disease does however mean we need to remain malleable with the above described patterns and our treatment strategies.

When considering echocardiographic findings in COVID-19, numerous mechanisms of cardiac injury have been described (figure 2). These include myocarditis, global cardiac dysfunction, right ventricular (RV) failure, and acute myocardial infarction (AMI).The ESC guidance on COVID-19 echocardiography advises only patients with cardiovascular compromise should be scanned, and these scans should be focused in nature (table 1) (5).

Myocarditis may occur secondary to the abundance of ACE2 receptors on cardiac myocytes -the binding site for SARS-CoV2, with echocardiographic findings described in myocarditis including:

 Global or regional left ventricular dysfunction (possibly resulting in misdiagnosis as AMI)

 Right ventricular dysfunction  Apparent left ventricular hypertrophy (secondary to interstitial oedema)  Ventricular thrombi (6) .

Right ventricular failure may be present as a result of raised pulmonary pressures (secondary to associated lung pathology, high ventilatory pressures or pulmonary thrombi), myocarditis or systemic hyperinflammation. Echocardiographic findings include RV dilation with impaired systolic function.

Global ventricular dysfunction and takotsubo cardiomyopathy have also been observed, presenting with a similar picture to that seen in septic cardiomyopathy. This is possibly a consequence of the hyperinflammatory stage of COVID-19 and is likely reversible (5,7). Acute myocardial infarction with associated regional wall motion abnormalities may also occur.

These can either be type 1 AMIs, as a result of infection driven plaque rupture, or type 2 AMIs due to insufficient myocardial perfusion.

Trans-oesophageal echocardiography (TOE) is another useful imaging modality in COVID-19. Often this patient group have difficult TTE windows, and thus TOE provides alternative (and often much clearer) cardiac views. Its use may however be limited by availability of skilled users, equipment, and the significant potential for aerosolisation. (8) POCUS may also have a role to play in management of COVID-19 associated cardiac arrest, as is recognised in the non-COVID-19 population (9). Barriers to its use are universal to scanning any patients with SARS-CoV2 infection undergoing aerosol generating procedures, namely the use of personal-protective equipment and challenges around disinfecting equipment (10).

Proposals regarding upskilling of the current workforce and rapid POCUS education have also been made, with a wealth of online and published resources becoming available (10).

In summary, in the face of a global pandemic, the ability to assess and triage patients in a rapid and reproducible manner is vital. When combined with clinical history and examination, POCUS provides a dynamic and low risk tool to help guide diagnosis and management. We thus feel that the use of lung US and echocardiography should be included in the clinical assessment and management of patients suffering from COVID-19. 

The BLUE-points: Three standardized points used in the BLUEprotocol for ultrasound assessment of the lung in acute respiratory failure

A Preliminary Study on the Ultrasonic Manifestations of Peripulmonary Lesions of Non-Critical Novel Coronavirus Pneumonia (COVID-19)

COVID-19 Pneumonia: Different Respiratory Treatment for Different Phenotypes? Intensive Care Medicine

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel

Non-invasive imaging in the diagnosis of acute viral myocarditis

Table 1. Summary of EACVI guidance on echocardiographic data in patients with